Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride
Brief Summary: The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes. Participants must also be taking metformin and glimepiride.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (Phase A)/Metformin (Phase B) | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d. | Intervention Type: DRUG; Name: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily); Assigned to Arm(s): 4, 5 | Intervention Type: DRUG; Name: Comparator: MK0431 100 mg q.d. (q.d. = once daily); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo (Phase A)/Metformin (Phase B); Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Comparator: Metformin 500 mg b.i.d.; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: Comparator: Metformin 1000 mg b.i.d.; Assigned to Arm(s): 3, 5
B: Arm Label: Arm 1 Treatment A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosiglitazone | Arm Label: Arm 2 Treatment B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Arm 1 Treatment A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Arm 2 Treatment B
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Arm Label: LY2189265 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: LY2189265 0.75 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: Insulin Glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine, Drug: Metformin, Drug: Glimepiride | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg

Answer: D